KAWAZOE Hitoshi

写真a

Affiliation

School of Medicine, Department of Clinical Pharmacy (Shinanomachi)

Position

Associate Professor

Career 【 Display / hide

  • 2024.06
    -
    Present

    慶應義塾大学病院薬剤部 副部長

  • 2024.06
    -
    Present

    慶應義塾大学医学部 准教授

  • 2022.04
    -
    2024.05

    慶應義塾大学薬学部 准教授

  • 2018.04
    -
    2022.03

    慶應義塾大学薬学部 専任講師

  • 2008.04
    -
    2018.03

    愛媛大学医学部附属病院 薬剤部

display all >>

Academic Background 【 Display / hide

  • 2004.04
    -
    2008.03

    The University of Tokushima, 薬科学教育部 医療生命薬学専攻 博士後期課程

    Graduate School, Completed, Doctoral course

  • 2001.04
    -
    2003.03

    The University of Tokushima, 薬学研究科 医療薬学専攻 博士前期課程

    Graduate School, Completed, Master's course

  • 1997.04
    -
    2001.03

    The University of Tokushima, 薬学部, 薬学科

    University, Graduated

Academic Degrees 【 Display / hide

  • 博士(薬学), The University of Tokushima, Coursework, 2008.03

    がん治療関連毒性に対する薬物療法に関する臨床薬学的研究

Licenses and Qualifications 【 Display / hide

  • 日本医療薬学会医療薬学専門薬剤師認定, 2020.01

  • 日本医療薬学会医療薬学指導薬剤師認定, 2020.01

  • 日本医療薬学会がん専門薬剤師認定, 2010.01

  • 日本医療薬学会がん指導薬剤師認定, 2010.01

  • 日本MBTI協会MBTI認定ユーザー, 2018.12

display all >>

 

Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy

Research Keywords 【 Display / hide

  • がん治療関連毒性の臨床薬学的研究

Research Themes 【 Display / hide

  • 卒前・卒後教育による次世代リーダー育成、がん薬物治療に関する薬効・安全性学的研究, 

    2021.04
    -
    Present

 

Books 【 Display / hide

  • がん薬物療法のひきだし~腫瘍薬学の基本から応用まで

    河添 仁, 医学書院, 2024.05,  Page: 112-118

    Scope: ホルモン療法薬

  • 調剤と情報7月増刊号

    菊山史博, 井上賀絵, 河添 仁, じほう, 2023.07,  Page: 294-307, 395-399

    Scope: 【こんなときはどの検定?臨床研究から学ぶ"逆引き"統計】第5章 分散分析と多重比較編 パラメトリック多重比較→Tukey-Kramer、Dunnett検定

  • 検査値と画像データから読み解く 薬効・副作用評価マニュアル

    河添 仁, 医学書院, 2022.08,  Page: 399-407

    Scope: 腫瘍マーカー・がん関連遺伝子検査

  • Principal Pharmacotherapy改訂3版

    河添 仁, ネオメディカル, 2022.03,  Page: 632-636

    Scope: 乳がん

  • 明日から使える免疫関連有害事象マネジメント 免疫チェックポイント阻害薬の看護ケア

    河添 仁, 南江堂, 2022.02,  Page: 105

    Scope: 編集にあたって

display all >>

Papers 【 Display / hide

  • Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer

    Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Kitagawa Y, Tsuchiya M, Kitahora M, Nagayama A, Kosaka S, Asano-Niwa Y, Seki T, Ohnuki K, Suzuki A, Ono F, Futamura M, Kawazoe H*, Nakamura T

    Oncologist (Oxford University Press)  29 ( 6 ) e741 - e749 2024.06

    Research paper (scientific journal), Joint Work, Corresponding author, Accepted,  ISSN  10837159

     View Summary

    Background: Proton pump inhibitors (PPIs) reduce the bioavailability of several anticancer drugs. The impact of PPIs co-administered with cyclin-dependent kinase 4 and 6 inhibitors is controversial. We aimed to clarify whether the concomitant use of PPIs impacts palbociclib and abemaciclib effectiveness in breast cancer treatment.
    Patients and Methods: This multicenter, retrospective, observational study, conducted across four medical institutions in Japan, consecutively included patients with endocrine-resistant metastatic breast cancer, receiving palbociclib or abemaciclib between December 2017 and August 2022. Propensity score-matched analyses were performed. Treatment efficacy and safety with and without PPIs were compared. Progression-free survival and overall survival were estimated using the Kaplan–Meier method and compared using a log-rank test. A Cox proportional hazards model was used to estimate the hazard ratio.
    Results: The study included 240 patients. After 1:1 matching, 112 patients were treated with and without PPIs. The median progression-free survival periods were 1.2 years in the PPI group and 1.3 years in the non-PPI group (hazard ratio, 1.19; 95% confidence interval [CI], 0.70–2.02). The median overall survival period was 3.6 years in the PPI group, whereas it was not reached in the non-PPI group (hazard ratio, 1.23; 95% CI, 0.61–2.47). Consistent results were obtained for subgroups receiving palbociclib (n = 177) and abemaciclib (n = 63) without propensity score matching. Moreover, adverse event incidence and severity were similar in both groups.
    Conclusion: The effectiveness of cyclin-dependent kinase 4/6 inhibitors is unlikely to be affected by concomitant PPI use. Future prospective pharmacokinetic studies are warranted.

  • Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial

    Iihara H, Iwai M, Morita R, Fujita Y, Ohgino K, Ishihara T, Hirose C, Suzuki Y, Masubuchi K, Kawazoe H, Kawae D, Aihara K, Endo S, Fukunaga K, Yamazaki M, Tamura T, Kitamura Y, Fukui S, Endo J, Suzuki A

    Lung Cancer (ELSEVIER IRELAND LTD)  192   107801 2024.04

    Research paper (scientific journal), Joint Work, Accepted

  • Using an online journal club to improve Asian speakers’ comfort in using English to discuss and understand research papers written in English

    Tsuchiya M, Saeteaw M, Subongkot S, Tharnpanich T, Konmun J, Nasu I, Shimanuki Y, Tsuchitani T, Ezura M, Hashiguchi K, Bryan JC, Kawazoe H*

    Journal of Oncology Pharmacy Practice (SAGE PUBLICATIONS LTD)  in press. 2024.03

    Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted

     View Summary

    Introduction: This study aimed to evaluate the participants’ comfort in understanding research papers written in English and discussing such research in English via an Asian online journal club.
    Methods: A self-administered online survey was delivered to seven journal club meeting attendees from July 2020 to July 2021. A customer satisfaction analysis was performed to assess the association between the participants’ perspectives on program logistics and satisfaction.
    Results: The recovery rate was 37.0% (44/119). After participating in the journal club, the median scores of critical appraisal skills, knowledge and/or pharmaceutical care skills in clinical practice, and discussion skills in English (assessed using a seven-point Likert scale) improved significantly (compared to pre-participation median scores) from 4 (interquartile range [IQR]: 3–5) to 5 (IQR: 4–6), 5 (IQR: 4–5) to 5 (IQR: 5–6), and 4 (IQR: 2–5) to 5 (IQR: 3–5), respectively (P < 0.0001). The respondents also expressed great appreciation for the benefits and overall qualities of the journal club. Additionally, regarding patient care behavior after participation in the journal club, 34 (77.3%), 17 (38.6%), 16 (36.4%), and 14 (31.8%) respondents reported improvement in “drug information services,” “patient assessments,” “patient counseling,” and “multidisciplinary rounds,” respectively. Customer satisfaction analysis revealed that sharing information, mutual discussion, a shift system of presenters and co-chairs, and session duration should be improved as a matter of highest priority.
    Conclusion: The findings suggest that our program could be helpful for Asian pharmacists, pharmacy students, and faculty members of the department of pharmacy.

  • Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E)

    Namiki T, Yokoyama Y, Hashi H, Oda R, Jibiki A, Kawazoe H, Matsumoto K, Suzuki S, Nakamura T

    Pharmacotherapy (WILEY)  44 ( 2 ) 149 - 162 2024.02

    Research paper (scientific journal), Joint Work, Accepted

  • Drug Repositioning Study on the Antiemetic Efficacy of Anamorelin for Cisplatin-Induced Nausea and Vomiting in Rats

    Nishino H†, Kawazoe H†*, Sekiguchi M, Jibiki A, Yokoyama Y, Suzuki S, Nakamura T

    BPB Reports (The Pharmaceutical Society of Japan)  7 ( 1 ) 1 - 6 2024.01

    Research paper (scientific journal), Joint Work, Corresponding author, Accepted

     View Summary

    Objective: Platinum- and anthracycline-based chemotherapy regimens cause nausea and vomiting in clinical practice, resulting in the deterioration of patients’ QoL, discontinuation of chemotherapy, and reduced therapeutic outcomes. Using pica behavior as an indicator, we aimed to clarify whether anamorelin, an orally active ghrelin receptor agonist, exerts antiemetic effects against cisplatin-induced nausea and vomiting in rats.
    Materials and methods: Sprague–Dawley rats were treated with cisplatin (5 mg/kg, i.p.), three-drug or four-drug antiemetics (granisetron [0.3 mg/kg, p.o.], dexamethasone [1.5 mg/kg, p.o.], fosaprepitant [12.5 mg/kg, i.p.], with or without anamorelin [30 mg/kg, p.o.]). Data on kaolin intake, normal food intake, and spontaneous motor activity (SMA) were recorded 1 d before and 5 d after cisplatin administration. Body weight (BW) was measured daily, and the percentage change in BW from baseline was calculated.
    Results: At the primary endpoint, kaolin intake was significantly higher in the cisplatin-only group than in the pretreatment and vehicle groups (p < 0.05). Additionally, kaolin food intake was not significantly low in cisplatin-treated mice treated with three-drug antiemetics with or without anamorelin. At the secondary endpoints, normal food intake, SMA, and percentage change in BW were significantly lower in the cisplatin-only group than in the vehicle group.
    Conclusion: Our findings suggest that the prophylactic administration of standard three-drug antiemetics, besides anamorelin, may not improve cisplatin-induced nausea and vomiting. Further studies using methods suitable for evaluating anamorelin levels are required.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • 病院薬剤師の働き方・キャリア形成に関する研究

    土屋 雅美, 笠師 久美子, 河添 仁, 大橋 裕丈, 小笠原 明美, 三好 由希子, 流石 学

    日本病院薬剤師会雑誌 ((一社)日本病院薬剤師会)  60 ( 10 ) 1167 - 1169 2024.10

    ISSN  1341-8815

  • 学習成果基盤型の薬学教育モデル・コア・カリキュラムに基づく実務実習の先行導入から実装後の取り組み評価

    河添 仁, 岩田紘樹, 石川春樹, 近藤慎吾, 地引 綾, 横山雄太, 小林典子, 鈴木小夜, 山浦克典, 中村智徳

    医療薬学 ((一社)日本医療薬学会)  50 ( 9 ) 455 - 464 2024.09

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work, Lead author, Corresponding author,  ISSN  1346-342X

  • Asia Pacific Oncology Pharmacy Congress 2024のご案内~国際的視点・人脈で活躍する薬剤師を目指して~

    河添 仁

    JSOPPニュースレター ((一社)日本がん薬剤学会)  21   3 - 4 2024.08

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work, Lead author, Last author, Corresponding author

  • 臨床的課題解決を目指した研究を行う次世代リーダーの養成~持続可能な研究活動を行うため~

    河添 仁

    薬学教育 ((一社)日本薬学教育学会)  7   129 - 131 2024.01

    Article, review, commentary, editorial, etc. (scientific journal), Lead author, Last author, Corresponding author,  ISSN  2432-4124

     View Summary

    薬学教育モデル・コア・カリキュラムの「薬剤師として求められる基本的な資質」の1つに「研究能力」がある.しかしながら,臨床現場にはギャップが存在するものと思われる.薬剤師は実臨床で生じた「臨床的疑問」を「研究的疑問」に変換して,臨床的課題解決を目指した研究に取り組むことができる.我々はこれまでに,臨床現場と薬学部が連携する研究環境を構築し,医療薬学研究のエビデンスを世界へ発信してきた.筆者は,学生や大学院生には「研究を行う意義」と「rationale」を自らの言葉で説明できるように指導している.すなわち,自らが行う研究成果を未来の患者へ還元する使命感や社会貢献のマインドセットを持つことが重要と考える.本稿では,我々が臨床的疑問から想起した臨床・基礎研究を紹介するとともに,臨床的課題解決を目指した研究を行う次世代リーダーの養成と持続可能な研究活動を行うための秘訣を述べる.(著者抄録)

  • 免疫チェックポイント阻害薬の有効性に影響を及ぼす併用薬と腸内細菌叢の臨床及び基礎研究

    河添 仁

    薬学研究の進歩 (公益財団法人薬学研究奨励財団)  39   71 - 75 2023.04

    Article, review, commentary, editorial, etc. (scientific journal), Single Work, Lead author, Last author, Corresponding author,  ISSN  0914-4544

display all >>

Presentations 【 Display / hide

  • 更年期女性における症状の相関解析

    地引 綾, 森岡由妃, 横田めぐみ, 堀場裕子, 吉野鉄大, 仁木晃子, 高畑海音子, 椎名美季, 大野あゆみ, 谷本慧子, 弟子丸亮太, 横山雄太, 河添 仁, 鈴木小夜, 山上 亘, 中村智徳

    第39回日本女性医学学会学術集会, 

    2024.11

    Oral presentation (general)

  • 胃酸分泌抑制薬がCDK4/6阻害薬の有効性と安全性に与える影響:傾向スコアマッチング解析

    岩部 翠, 高橋佳織, 魚住龍史, 向原 徹, 林田 哲, 飯原大稔, 楠原佳那子, 土屋雅美, 北洞美佳, 永山愛子, 小坂真吉, 丹羽好美, 関 朋子, 大貫幸二, 鈴木昭夫, 二村 学, 河添 仁, 中村智徳

    第34回日本医療薬学会年会, 

    2024.11

    Oral presentation (general)

  • Preventive Effects of Non-sedating Antihistamines Premedication on Subcutaneous Daratumumab-Associated Infusion-Related Reactions: A Prospective Cohort Study

    Suzukawa M, Aomori T, Suehiro N, Kiyomiya K, Hiroomi Sakurai H, Kawazoe H, Ohtani H

    Asia Pacific Oncology Pharmacy Congress 2024, Tokyo, 

    2024.10

    Poster presentation

  • 肥満マウスモデルにおける防風通聖散、防已黄耆湯及び大柴胡湯の体脂肪蓄積抑制効果と腸内細菌叢変化の比較

    仲道公輔, 地引 綾, 横山雄太, 河添 仁, 鈴木小夜, 吉野鉄大, 渡辺賢治, 秋山雅博, 金 倫基, 中村智徳

    第41回和漢医薬学会学術大会, 

    2024.08

    Oral presentation (general)

  • Use of proton pump inhibitors and cyclin-dependent kinase 4/6 inhibitors in patients with endocrine-resistant metastatic breast cancer

    Kawazoe H, Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Kitagawa Y, Tsuchiya M, Kitahora M, Nagayama A, Kosaka S, Asano-Niwa Y, Seki T, Ohnuki K, Suzuki A, Ono F, Futamura M, Nakamura T

    MASCC/AFSOS/ISOO 2024 Annual Meeting, Lille, 

    2024.06

    Poster presentation

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 生菌製剤が免疫チェックポイント阻害薬の有効性に与える影響の解明に向けた基礎・臨床一体型研究

    2024.06
    -
    2025.03

    公益財団法人政策医療振興財団, (公財)政策医療振興財団研究助成, Research grant, Principal investigator

  • 生菌製剤が免疫チェックポイント阻害薬の抗腫瘍効果に与える影響の基礎・臨床融合研究

    2024.04
    -
    2025.03

    慶應義塾, 慶應義塾学事振興資金, Research grant, Principal investigator

  • CDK4/6阻害薬と胃酸分泌抑制薬の薬物相互作用の解明に向けた臨床・基礎融合研究

    2023.06
    -
    2024.03

    公益財団法人政策医療振興財団, (公財)政策医療振興財団研究助成, Research grant, Principal investigator

  • パルボシクリブと胃酸分泌抑制薬の薬物相互作用の臨床・基礎融合研究

    2023.04
    -
    2024.03

    慶應義塾, 福澤基金研究補助, Research grant, Principal investigator

  • バンコマイシンのAUC指標TDMの臨床実装とその評価

    2022.12
    -
    2025.03

    公益財団法人ファイザーヘルスリサーチ振興財団, 第31回(2022年度)ヘルスリサーチ研究助成 国内共同研究(年齢制限なし), Research grant, Principal investigator

display all >>

Awards 【 Display / hide

  • 日本臨床腫瘍薬学会学術大会2024優秀演題賞

    北洞美佳, 魚住龍史, 髙橋佳織, 向原 徹, 林田 哲, 岩部 翠 , 飯原大稔, 河添 仁, 楠原佳那子, 永山愛子, 土屋雅美, 丹羽好美, 中村智徳, 小坂真吉, 二村 学, 関 朋子, 大貫幸二, 鈴木昭夫, 2024.03, 日本臨床腫瘍薬学会学術大会2024, CDK4/6阻害薬の有効性に対するプロトンポンプ阻害薬併用の影響:多機関共同後方視的観察研究

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第44回日本臨床薬理学会学術総会優秀発表賞

    並木孝哉, 横山雄太, 枦 秀樹, 織田錬太郎, 地引 綾, 河添 仁, 松元一明, 鈴木小夜, 中村智徳, 2023.12, 第44回日本臨床薬理学会学術総会, 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第8回日本薬学教育学会大会優秀発表賞

    牧山大輝, 松野昂樹, 小林聡太, 野々宮菜彌, 地引 綾, 横山雄太, 河添 仁, 津田壮一郎, 大谷壽一, 中村智徳, 鈴木小夜, 2023.08, 第8回日本薬学教育学会大会, フィードバックと省察ワークシートによる介入が病院実務実習生のプロフェッショナリズム評価と省察能力に与えた影響

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第16回日本性差医学・医療学会学術集会優秀演題賞

    地引 綾, 村上紗恵子, 吉野鉄大, 堀場裕子, 横山雄太, 河添 仁, 鈴木小夜, 渡辺賢治, 中村智徳, 2023.02, 第16回日本性差医学・医療学会学術集会, 更年期症状に対する漢方治療不応例の分析

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第32回日本医療薬学会年会 YIA(Young Investigator's Award)(社会人部門)

    並木孝哉, 横山雄太, 枦 秀樹, 地引 綾, 河添 仁, 松元一明, 鈴木小夜, 中村智徳, 2022.09, 第32回日本医療薬学会年会, ESBL産生腸内細菌科細菌に対する血液透析患者の遊離形CMZ濃度を用いたPK/PDに基づく最適投与法の評価

    Type of Award: Award from Japanese society, conference, symposium, etc.

display all >>

 

Courses Taught 【 Display / hide

  • ADVANCED DRUG INFORMATICS

    2024

  • ADVANCED PRACTICAL TRAINING IN A HOSPITAL (ABROAD)

    2024

  • STUDY OF MAJOR FIELD: (PHARMACEUTICAL CARE SCIENCES)

    2024

  • SEMINAR: (PHARMACEUTICAL CARE SCIENCES)

    2024

  • RESEARCH FOR BACHELOR'S THESIS 1

    2024

display all >>

Courses Previously Taught 【 Display / hide

  • 薬学英語演習S

    Keio University

    2018.04
    -
    2019.03

  • 卒業研究C

    Keio University

    2018.04
    -
    2019.03

  • 卒業研究B

    Keio University

    2018.04
    -
    2019.03

  • 卒業研究A

    Keio University

    2018.04
    -
    2019.03

  • 薬局実務実習

    Keio University

    2018.04
    -
    2019.03

display all >>

 

Social Activities 【 Display / hide

  • 日本医療薬学会 2024年度医療薬学学術第3小委員会「生成系AIの薬剤師業務への応用に関する実態、課題やニーズの調査」研究班

    2024.04
    -
    2026.03
  • 日本病院薬剤師会 令和5年度学術第6小委員会「病院薬剤師の働き方・キャリア支援」研究班

    2023.07
    -
    2025.06
  • 日本がん薬剤学会 研究推進委員会

    2022.06
    -
    Present
  • 日本臨床腫瘍薬学会 実地研修委員会

    2022.04
    -
    Present
  • 日本臨床腫瘍薬学会 理事

    2022.03
    -
    2024.03

display all >>

Memberships in Academic Societies 【 Display / hide

  • Multinational Association of Supportive Care in Cancer (MASCC), 

    2024.04
    -
    Present
  • 日本がん薬剤学会, 

    2022.04
    -
    Present
  • 日本薬学会, 

    2019.08
    -
    Present
  • 日本MBTI協会, 

    2018.12
    -
    Present
  • 東京都病院薬剤師会, 

    2018.04
    -
    Present

display all >>